CD8A and neoplasm: Taken together, we have identified a β-catenin/Tim-3 axis in DCs that negatively regulates anti-tumor CD8 T cell immunity and that combination immunotherapy of a DC-targeted vaccine with anti-Tim-3 antibody leads to improved anti-tumor efficacy.